iBio (IBIO)

0.4099 +0.01  +2.50%  May 17, 8:00PM
Add to Watchlists Create an Alert

iBio R&D Expense Quarterly:

0.6558M for Dec. 31, 2012
View Full Chart

iBio R&D Expense Quarterly Chart

    iBio Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    Dec. 31, 2012 0.6558M
    Sept. 30, 2012 1.178M
    June 30, 2012 1.055M
    March 31, 2012 1.307M
    Dec. 31, 2011 1.162M
    Sept. 30, 2011 1.457M
    June 30, 2011 1.169M
    March 31, 2011 1.137M
    Dec. 31, 2010 0.6195M
    Sept. 30, 2010 0.1575M
    June 30, 2010 1.103M
       
    March 31, 2010 1.056M
    Dec. 31, 2009 0.2542M
    Sept. 30, 2009 0.1042M
    June 30, 2009 0.0831M
    March 31, 2009 0.0831M
    Dec. 31, 2008 0.3191M
    Sept. 30, 2008 0.25M
    June 30, 2008 0.2928M
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    IBIO R&D Expense Quarterly Benchmarks

    Companies
    Acura Pharmaceuticals 2.026M
    Horizon Pharma 4.739M
    Sagent Pharmaceuticals 4.261M

    IBIO R&D Expense Quarterly Rankings

    Overall 83rd percentile
    1356 of 8007
    Sector 39th percentile
    413 of 685 in Healthcare
    Industry 22nd percentile
    53 of 68 in Drug Manufacturers - Specialty & Generic

    IBIO R&D Expense Quarterly Range, Past 5 Years

    Minimum 0.0831M Mar 2009
    Maximum 1.457M Sep 2011
    Average 0.7075M